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Parkinson’s disease (PD) is a neurodegenerative disorder that affects about 1.5% of the
global population over 65 years of age. A hallmark feature of PD is the degeneration of the
dopamine (DA) neurons in the substantia nigra pars compacta (SNc) and the consequent
striatal DA deﬁciency. Yet, the pathogenesis of PD remains unclear. Despite tremendous
growth in recent years in our knowledge of the molecular basis of PD and the molecular
pathways of cell death, important questions remain, such as: (1) why are SNc cells
especially vulnerable; (2) which mechanisms underlie progressive SNc cell loss; and (3)
what do Lewy bodies or α-synuclein reveal about disease progression. Understanding the
variable vulnerability of the dopaminergic neurons from the midbrain and the mechanisms
whereby pathology becomes widespread are some of the primary objectives of research
in PD. Animal models are the best tools to study the pathogenesis of PD.The identiﬁcation
of PD-related genes has led to the development of genetic PD models as an alternative to
the classical toxin-based ones, but does the dopaminergic neuronal loss in actual animal
models adequately recapitulate that of the human disease? The selection of a particular
animal model is very important for the speciﬁc goals of the different experiments. In this
review, we provide a summary of our current knowledge about the different in vivo models
of PD that are used in relation to the vulnerability of the dopaminergic neurons in the
midbrain in the pathogenesis of PD.
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INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative disor-
der whose prevalence increases with age (Pringsheim et al., 2014).
The cardinal features of PD include tremor, rigidity and slowness
of movements, albeit non-motor manifestations such as depres-
sion and sleep disturbances are increasingly recognized in these
patients (Rodriguez-Oroz et al., 2009). Over the past decade,more
attention has also been paid to the broader nature of the neu-
rodegenerative changes in the brains of PD patients. Indeed, for
many years, the neuropathological focus has been on the strik-
ing neurodegeneration of the nigrostriatal dopaminergic pathway,
however, nowadays, disturbances of the serotonergic, noradrener-
gic, glutamatergic, GABAergic, and cholinergic systems (Brichta
et al., 2013) as well as alterations in neural circuits are now being
intensively investigated from the angle of the pathophysiology of
PD (Obeso et al., 2014), with the underlying expectation of acquir-
ing a better understanding of the neurobiology of this disabling
disorder and of identifying new targets for therapeutic purposes.
From a molecular biology point of view, the accepted opinion
that the PD neurodegenerative process affects much more than
the dopaminergic neurons of the substantia nigra pars compacta
(SNc), has triggered a set of fascinating questions such as: are
dopaminergic and non-dopaminergic neurons in PD dying by the
same pathogenic mechanisms; and, given the fact that within a
given subtype of neurons, not all die to the same extent nor at
the same rate [e.g., dopaminergic neurons in the SNc vs. ventral
tegmental area (VTA)], what are the molecular determinants of
susceptibly/and resistance to disease?
To gain insights into these types of critical questions, a brief
review of the literature demonstrates that the enthusiasm for
experimental models of PD, both in vitro and in vivo, has greatly
increased, in part, thanks to new strategies for producing sophisti-
catedmodels, such as the temporal- and/or cell-speciﬁc expression
of mutated genes in mice (Dawson et al., 2010), human pluripo-
tent cells coaxed into a speciﬁc type of neurons (Berg et al., 2014),
and a host of invertebrate organisms like Drosophila (Guo, 2012),
Caenorhabditis elegans (Chege and McColl, 2014), or Medaka ﬁsh
(Matsui et al., 2014). Thus far, however, all of these experimen-
tal models continue to be categorized into two main ﬂavors: toxic
and genetic (and sometimes, both approaches are combined). But,
more importantly, none of the currently available models pheno-
copyPD,mainly because they lack some speciﬁcneuropathological
and/or behavioral feature of PD. Some PD experts see this as fatal
ﬂaws, while others tend to ignore the shortcomings. It has always
been our personal view that models are just models and, as such,
given the large collection of models the ﬁeld of PD possesses, the
prerequisite resides in not using just any model but in selecting the
optimal in vitro or in vivo model whose strengths are appropriate
for investigating the question being asked and whose weaknesses
will not invalidate the interpretation of an experiment.
Based on our above premise, herein, we discuss the experimen-
talmodels of PD,with a deliberate emphasis on in vivomammalian
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Table 1 | Animal models of Parkinson disease.
Animal model Motor behavior SNc neuron loss Striatal DA loss Lewy body/Syn
pathology
Toxin-based MPTP Mice Reduced locomotion, bradykinesia ↑ ↑ ↑ ↑ ↑ ↑ NO
MPTP Monkeys Reduced locomotion, altered behavior,
tremor, and rigidity
↑ ↑ ↑ ↑ ↑ ↑ NO
6-OHDA rat Reduced locomotion, altered behavior ↑ ↑ ↑ ↑ ↑ ↑ NO
Rotenone Reduced locomotion ↑ ↑ ↑ ↑ ↑ YES
Paraquat/maneb Reduced locomotion ↑ ↑ ↑ ↑ ↑ YES
MET/MDMA Reduced locomotion ↑ ↑ ↑ ↑ ↑ NO
Genetic mutations* α-Synuclein Altered behavior, reduced or increased
motor activity
↑ Not consistent ↑ ↑ (in old animals)
LRKK2 Mild behavioral alteration NO NO NO
PINK1 No obvious alterations or reduced
locomotion
NO NO NO
PARKIN No obvious locomotion or reduced
locomotion
NO ↑ NO
DJ-1 Decreased locomotor activity NO NO NO
ATP13A2 Late onset sensorimotor deﬁcits NO NO NO
Others SHH Reduced locomotion ↑ ↑ ↑ ↑ NO
Nurr1 Reduced locomotion ↑ ↑ ↑ ↑ NO
Engrailed 1 Reduced locomotion ↑ ↑ ↑ NO
Pitx3 Reduced locomotion ↑ ↑ ↑ ↑ ↑ ↑ NO
C-Rel-NFKB Gait, bradykinesia, rigidity ↑ ↑ ↑ ↑ YES
MitoPark Reduced locomotion, tremor, and rigidity ↑ ↑ ↑ ↑ YES
Atg7 Late onset locomotor deﬁcits ↑ ↑ ↑ ↑ YES
VMAT2 Reduced locomotion and altered behavior ↑ ↑ ↑ ↑ YES
↑ ↑ ↑, Severe loss; ↑ ↑, Moderate loss; ↑, Mild loss.
*This table summarizes general observations for each model. See the main text for full and speciﬁc description of different animal models for each genetic mutation.
models induced by reproducible means. Over the years, a constel-
lation of uncommon strategies and organisms have been used
to produce models of PD. However, in this review, we have
decided not to discuss these cases, because we have limited space
and because we are missing sufﬁcient independent information
to assessment the reproducibility and reliability of these models,
which, to us, is critical for distinguishing between interesting “case
reports” and useful tools to model human diseases.
TOXIN MODELS
A number of pharmacological and toxic agents including reser-
pine, haloperidol, and inﬂammogens like lipopolysaccharide have
been used over the years to model PD, although the two most
widely used are still the classical 6-OHDA in rats and MPTP in
mice and monkeys. Although the neurotoxic models appear to be
the best ones for testing degeneration of the nigrostriatal path-
way, some striking departures from PD need to be mentioned: the
degeneration of dopaminergic neurons progress rapidly, i.e., days
not years, lesions are primarily if not exclusively dopaminergic,
and animals lack the typical PD proteinaceous inclusions called
Lewy bodies (LBs). In addition, behavioral abnormalities in these
animalmodels are also a challenging question (see below; Table 1).
MPTP
MPTP is the tool of choice for investigations into the mechanisms
involved in the death of DA neurons in PD. MPTP has been shown
to be toxic in a large range of species (Tieu, 2011). The most pop-
ular species, besides primates, is the mouse, as rats were found
to be resistant to this toxin (Chiueh et al., 1984). A number of
intoxication regimens or administration methods have been used
over the years in mouse (Jackson-Lewis and Przedborski, 2007;
Meredith et al., 2008) and in primates (Bezard et al., 1997; Blesa
et al., 2012; Porras et al., 2012). In both species, MPTP primarily
causes damage to the nigrostriatal DA pathway with a profound
loss of DA in the striatum and SNc (Dauer and Przedborski,
2003).
This speciﬁc and reproducible neurotoxic effect on the nigros-
triatal system is the strength of thismodel. Neuropathological data
show that MPTP administration causes damage to the nigrostri-
atal DA pathway that is identical to that seen in PD (Langston
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et al., 1983), yet there is a resemblance that goes beyond the loss
of SNc DA neurons. Like in PD, MPTP causes greater loss of DA
neurons in SNc than in VTA or retrorubral ﬁeld (Seniuk et al.,
1990; Muthane et al., 1994; Blesa et al., 2011, 2012) and, at least
in monkeys treated with low doses of MPTP, greater degenera-
tion of DA nerve terminals in the putamen than in the caudate
nucleus (Moratalla et al., 1992; Snow et al., 2000; Blesa et al.,
2010).
A often raised weakness with this model is the lack of LB (Shi-
moji et al., 2005; Halliday et al., 2009). Although no LBs have been
observed in these models so far, a few reports have investigated
the expression, regulation or pattern of α-syn after MPTP expo-
sure (Vila et al., 2000; Dauer et al., 2002; Purisai et al., 2005). Only,
in MPTP-injected monkeys, have intraneuronal inclusions, rem-
iniscent of LBs, been described (Forno et al., 1986; Kowall et al.,
2000). Behavior is also an issue, and except for the monkeys, fea-
tures reminiscent of PD are lacking especially in mice. Yet, using
a battery of tests, some motor alterations in mice with profound
dopaminergic deﬁcit may be detected (Taylor et al., 2010).
6-OHDA
Like MPTP, 6-OHDA is a selective catecholaminergic neurotoxin
that is used, mainly, to generate lesions in the nigrostriatal DA
neurons in rats (Ungerstedt, 1968). Since 6-OHDA cannot cross
the blood-brain barrier, systemic administration fails to induce
parkinsonism. So, this induction model requires that 6-OHDA be
injected (typically as a unilateral injection) into the SNc, medial
forebrain bundle or striatum (Blandini et al., 2008). Intraventric-
ular administration has also been achieved (Rodríguez Díaz et al.,
2001). The effects resemble those in the acute MPTP model, caus-
ing neuronal death over a brief time course (12 h to 2–3 days). The
intrastriatal injection of 6-OHDA causes progressive retrograde
neuronal degeneration in the SNc and VTA (Sauer and Oertel,
1994; Przedborski et al., 1995). The pattern of DA loss in animals
bearing a full lesion (>90%) again mirrors seen that in PD, with
the SNc showingmore cells loss compared to theVTA (Przedborski
et al., 1995). As in PD,DA neurons are killed, and the non-DA neu-
rons are preserved. However, like in the MPTP model, 6-OHDA
does not produce LB-like inclusions in the nigrostriatal pathway.
Traditionally, behavioral assessments of motor impairments in
the unilateral 6-OHDA model are done by drug-induced rotation
tests (Dunnett and Lelos, 2010). However, drug-free sensorimotor
behavioral tests have been developed in both rat andmice thatmay
be helpful for the preclinical testing of new symptomatic strategies
(Schallert et al., 2000; Glajch et al., 2012).
ROTENONE
Chronic systemic exposure to rotenone in rats causes many fea-
tures of PD, including nigrostriatal DA degeneration (Betarbet
et al., 2000). The rotenone-administered animal model also repro-
duces all of the behavioral features reminiscent of human PD.
Importantly, many of the degenerating neurons have intracellu-
lar inclusions that resemble LB morphologically. These inclusions
show immunoreactivity for α-syn and ubiquitin as did the origi-
nal LB (Sherer et al., 2003). Usually, rotenone is administered by
daily intraperitoneal injection (Cannon et al., 2009), intravenously
or subcutaneously (Fleming et al., 2004). Recently, rotenone has
been tested in mice through chronic intragastric administration,
(Pan-Montojo et al., 2010) or as a stereotaxic injection or infu-
sion directly in the brain (Alam et al., 2004; Xiong et al., 2009)
recapitulating the slow and speciﬁc loss of DA neurons. How-
ever, administration of rotenone in rats causes high mortality and,
somehow, is difﬁcult to replicate.
PARAQUAT/MANEB
Although the idea that the herbicide paraquat (N,N′-dimethyl-
4-4-4′-bypiridinium), may cause parkinsonism in humans has
attracted some interest, at this time, as pointed out by Berry
and collaborators, epidemiological and clinical evidence that
paraquat may cause PD is inconclusive (Berry et al., 2010). And,
the same view seems to apply to the fungicide maneb (man-
ganese ethylenebisdithiocarbamate; Berry et al., 2010). Moreover,
effects of this compound in the nigrostriatal DA system is some-
what ambiguous (Freire and Koifman, 2012). Regarding animal
models, some researchers report that, following the systemic appli-
cation of paraquat, mice exhibit reduced motor activity and a
dose-dependent loss of striatal tyrosine hydroxylase (TH) ﬁbers
and SNc neurons with relative sparing of the VTA (Brooks et al.,
1999; Day et al., 1999; McCormack et al., 2002; Rappold et al.,
2011). Like rotenone, paraquat may be useful in the laboratory
because of its presumed ability to induce LB in DA neurons
(Manning-Bog et al., 2002). Maneb has been shown to decrease
locomotor activity and produce SNc neurons loss (Thiruchelvam
et al., 2003) and potentiate both theMPTP and the paraquat effects
(Takahashi et al., 1989; Thiruchelvam et al., 2000; Bastías-Candia
et al., 2013). However, as with rotenone, this model shows contra-
dictory results, variable cell death and loss of striatal DA content
(Miller, 2007).
AMPHETAMINE-TYPE PSYCHOSTIMULANTS
Some amphetamine derivatives such as methamphetamine
(METH) and 3,4-methylenedioxymethamphetamine (MDMA)
also have neurotoxic effects on the nervous system causing not
only functional deﬁcits but also structural alterations (Cadet et al.,
2007; Thrash et al., 2009). The ﬁrst study to show DA depletion in
rats following repeated, high-dose exposure to METH was con-
ducted by Kogan et al. (1976). Hess et al. (1990) and Sonsalla
et al. (1996) showed that high-dose treatment with METH in mice
resulted in a loss of DA cells in the SNc. Since then, several studies
have reported selective DA or serotonergic nerve terminal as well
as SNc neuronal loss in rodents, primates or even guinea pig fol-
lowing the administration of very high doses of METH (Wagner
et al., 1979; Trulson et al., 1985; Howard et al., 2011; Morrow et al.,
2011).
3,4-Methylenedioxymethamphetamine can also elicit signiﬁ-
cant neurobehavioral adverse effects. Although MDMA toxicity
mainly affects the serotonergic system, DA system can also be
affected to a lesser extent (Jensen et al., 1993; Capela et al., 2009).
In mice, repeated administration of MDMA produces degener-
ation of DA terminals in the striatum (O’Callaghan and Miller,
1994; Granado et al., 2008a,b) and TH+ neuronal loss in the SNc
(Granado et al., 2008b).
Exposure to low concentrations of METH results in a decrease
of the vulnerability of the SNc DA cells to toxins like 6-OHDA or
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MPTP (Sziráki et al., 1994; El Ayadi and Zigmond, 2011). On the
other hand, chronic exposure to MDMA of adolescent mice exac-
erbatesDAneurotoxicity elicited byMPTP in the SNc and striatum
at adulthood (Costa et al., 2013). Hence, a METH or MDMA-
treated animal model could be useful to study the mechanisms of
DA neurodegeneration (Thrash et al., 2009).
GENETIC MODELS
Genetic models may better simulate the mechanisms underly-
ing the genetic forms of PD, even though their pathological and
behavioral phenotypes are often quite different from the human
condition. A number of cellular and molecular dysfunctions have
been shown to result from these gene defects like fragmented
and dysfunctional mitochondria (Exner et al., 2012; Matsui et al.,
2014; Morais et al., 2014), altered mitophagy (Lachenmayer and
Yue, 2012; Zhang et al., 2014), ubiquitin–proteasome dysfunction
(Dantuma and Bott, 2014), and altered reactive oxygen species
production and calcium handling (Gandhi et al., 2009; Joselin
et al., 2012; Ottolini et al., 2013). Some studies have reported alter-
ations in motor function and behavior in these mice (Hinkle et al.,
2012; Hennis et al., 2013; Vincow et al., 2013), and sensitivities to
complex I toxins, like MPTP, different from wild type (WT) mice
(Dauer et al., 2002; Nieto et al., 2006; Haque et al., 2012) although
this latter ﬁnding is not always consistent (Rathke-Hartlieb et al.,
2001; Dong et al., 2002). However, almost all of the studies evalu-
ating the integrity of the nigrostriatal DA system in these genetic
models failed to ﬁnd signiﬁcant loss of DA neurons (Goldberg
et al., 2003; Andres-Mateos et al., 2007; Hinkle et al., 2012; Sanchez
et al., 2014). Thus, recapitulation of the genetic alterations in mice
is insufﬁcient to reproduce the ﬁnal neuropathological feature
of PD. Below, we describe transgenic mice or rat models which
recapitulate the most known mutations observed in familial PD
patients (Table 1).
α-SYNUCLEIN
α-syn was the ﬁrst gene linked to a dominant-type, familial PD,
called Park1, and is the main component of LB which are observed
in the PDbrain (Goedert et al., 2013). Threemissensemutations of
α-syn, encoding the substitutionsA30P,A53T,andE46K,have been
identiﬁed in familial PD so far (Vekrellis et al., 2011; Schapira et al.,
2014). Furthermore, the duplication or triplication of α-syn is
sufﬁcient to cause PD, suggesting that the level of α-syn expression
is a critical determinant of PD progression (Singleton et al., 2003;
Kara et al., 2014).
To date, various α-syn transgenic mice have been developed.
Although, in some of these mice, decreased striatal levels of TH or
DA and behavioral impairments indicate that the accumulation
of α-syn can signiﬁcantly alter the functioning of DA neurons,
no signiﬁcant nigrostriatal degeneration has been found in most
of them. The models of α-syn overexpression in mice recapitu-
late the neurodegeneration, depending primarily on the promoter
used to drive the expression of the transgene, whether the trans-
gene codes for the WT or the mutated protein, and the level of
expression.
Although a lot of behavioral alterations have been described in
both the A30P and A53T mice (Sotiriou et al., 2010; Oaks et al.,
2013; Paumier et al., 2013), the mouse prion protein promoter
failed to reproduce the cell loss in the SNc or locus coeruleus
(LC; van der Putten et al., 2000; Giasson et al., 2002; Gispert et al.,
2003). The same phenotype was found with the hamster prion
promoter (Gomez-Isla et al., 2003). Mice based on the PDGF-β
promoter showed loss of terminals and DA in the striatum but no
TH+ cell loss (Masliah et al., 2000). The TH promoter led to TH+
cell loss only in a few studies (Thiruchelvam et al., 2004; Waka-
matsu et al., 2008) but did not replicate the α-syn neuropathology
as did the Thy-1 promoter (Matsuoka et al., 2001; Chen et al.,
2006; Miller et al., 2007; Su et al., 2009). However, the use of
the murine Thy-1 promoter often causes loss of DA levels in the
striatum but only moderate nigral DA cell loss in the SNc, with
α-syn pathology (van der Putten et al., 2000; Rockenstein et al.,
2002; Ikeda et al., 2009; Ono et al., 2009; Lam et al., 2011). A new
line of tetracycline-regulated inducible transgenic mice that over-
expressed α-syn A53T under control of the promoter of Pitx3
in the DA neurons developed profound motor disabilities and
robust midbrain neurons neurodegeneration, profound decrease
of DA release, the fragmentation of Golgi apparatus, and the
impairments of autophagy/lysosome degradation pathways (Lin
et al., 2012). Janezic et al. (2013) generated BAC transgenic mice
(SNCA-OVX) that expressWT human α-syn and which display an
age-dependent loss of SNc DA neurons preceded by early deﬁcits
in DA release from terminals in the dorsal striatum, protein aggre-
gation and reduced ﬁring of SNc DA neurons. Regarding the
transgene expressed, the A53T seems to be more effective than
the A30P, in general.
Several viral vectors, primarily lentiviruses and adeno-
associated viruses (AAVs), have been used to drive exogenous
α-syn. Rats are usually used for these studies because viral vec-
tor delivery requires stereotactic injections within or near the site
of the neuronal cell bodies in the SNc (Kirik et al., 2002; Klein
et al., 2002; Lo Bianco et al., 2002; Lauwers et al., 2003, 2007). In
contrast to all of the α-syn transgenic mice, viral vector-mediated
α-syn models display α-syn pathology and clear dopaminergic
neurodegeneration. The injection of human WT or A53T mutant
α-syn by AAVs into the SNc neurons of rats induces a progres-
sive, age-dependent loss of DA neurons, motor impairment, and
α-syn cytoplasmic inclusions (Kirik et al., 2002; Klein et al., 2002;
Lo Bianco et al., 2002; Decressac et al., 2012). This cell loss was
preceded by degenerative changes in striatal axons and terminals,
and the presence of α-syn positive inclusions in axons and den-
drites (Kirik et al., 2003; Decressac et al., 2012). These results have
been replicated in mice (Lauwers et al., 2003; Oliveras-Salvá et al.,
2013). Although these models still suffer from a certain degree of
variability, they can be of great value for further development and
testing of neuroprotective strategies.
Recently, several studies have demonstrated that α-syn may
be transmissible from cell to cell (Luk and Lee, 2014). In WT
mice, a single intrastriatal inoculation of synthetic α-syn ﬁbrils
or pathological α-syn puriﬁed from postmortem PD brains led to
the cell-to-cell transmission of pathologic α-syn and LB pathol-
ogy in anatomically interconnected regions and was accompanied
by a progressive loss of dopaminergic neurons in the SNc and
reduced DA levels in the striatum, culminating in motor deﬁcits
(Luk et al., 2012a,b; Masuda-Suzukake et al., 2014; Recasens et al.,
2014). Moreover, the hind limb intramuscular injection of α-syn
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can induce pathology in the central nervous system in transgenic
mouse models (Sacino et al., 2014).
LRKK2
Mutations in LRRK2 are known to cause a late-onset autosomal
dominant inherited form of PD (Healy et al., 2008). Several muta-
tions have been identiﬁed in LRRK2, the most frequent being the
G2019Smutation, a pointmutation in the kinase domain, whereas
R1441C, a mutation in the guanosine triphosphatase domain, is
the second most common (Rudenko and Cookson, 2014). Overall,
LRRK2 mice models display mild or not functional disruption of
the nigrostriatal DA neurons of the SNc.
LRRK2 KO mice are viable and have an intact nigrostriatal DA
pathway up to 2 years of age. Neuropathological features associ-
ated with neurodegeneration or altered neuronal structure were
absent, but α-syn or ubiquitin accumulation has been reported
in these mice (Andres-Mateos et al., 2009; Lin et al., 2009; Tong
et al., 2010; Hinkle et al., 2012). To date, two LRRK2 KO rat mod-
els have been developed, although the consequences of LRRK2
deﬁciency in the brain are still unknown (Baptista et al., 2013;
Ness et al., 2013).
Both G2019S and R1441C LRRK2 KI mice are viable, fer-
tile, and appear grossly normal. This mutation had no impact
on DA neuron number or morphology in the SNc, or on nora-
drenergic neurons in the LC. Striatal DA levels and DA turnover
are also normal in these mice (Tong et al., 2009; Herzig et al.,
2011).
Overexpression of G2019S LRRK2 leads to a mild progres-
sive and selective degeneration of SNc DA neurons (20%) up to
2 years of age. Furthermore, no alteration in striatal DA levels
or locomotor activity could be detected in older G2019S LRRK2
mice (Ramonet et al., 2011; Chen et al., 2012). Also, Maekawa
et al. (2012) generated transgenic mice constitutively expressing
V5-tagged human I2020T LRRK2 from a CMV promoter with
no inﬂuence on SNc DA neuronal number or striatal DA ﬁber
density. Zhou et al. (2011) developed a transgenic rat model
expressing G2019S LRRK2. Despite a mild behavioral alteration,
LRRK2 expression had no effect on the number of DA neurons
or on striatal DA content. Recently, conditional expression of
R1441CLRRK2 inmidbrain dopaminergic neurons of mice results
in nuclear abnormalities but, without neurodegeneration (Tsika
et al., 2014).
Additional LRRK2 BAC transgenic mouse models have also
been developed. These mice displayed age-dependent and pro-
gressive motor deﬁcits at 10–12 months of age, accompanied by a
mild reduction of striatal DA release. Adult neurogenesis and neu-
rite outgrowth are impaired. No DA neurons loss or degeneration
of striatal nerve terminals where observed in mice at 9–10 months
of age (Li et al., 2009b, 2010; Melrose et al., 2010; Winner et al.,
2011).
Regarding the viral vector-basedmodels, Lee et al. (2010) devel-
oped a herpes simplex virus (HSV) amplicon-based mouse model
of G2019S LRRK2-induced DA neurotoxicity. The nigrostriatal
expression of WT LRRK2 induced modest nigral DA neurodegen-
eration (10–20%), whereas expression of the kinase-hyperactive
G2019S LRRK2 resulted in a 50% neuronal loss in the ipsilateral
SNc associated with reduced striatal DA ﬁber density at 3 weeks
post-injection. In another study, a model based on the unilateral
injection of recombinant, second-generation human serotype 5
adenoviral (rAd) vectors expressing FLAG-tagged human WT or
G2019S LRRK2 driven by a neuronal-speciﬁc human synapsin-1
promoter in rats induced the progressive loss (20%) of DA neu-
rons in the ipsilateral SNc over 42 days, but with no reduction of
striatal DA ﬁber density (Dusonchet et al., 2011).
PINK1
Mutations in the gene PINK1 cause another form of PD called
PARK6 (Scarffe et al., 2014). PINK1 KO mice have an age-
dependent, moderate reduction in striatal DA levels accompanied
by low locomotor activity, but do not exhibit major abnormali-
ties in the DA neurons or striatal DA levels (Gautier et al., 2008;
Gispert et al., 2009). These mice showed no LB formation or
nigrostriatal degeneration for up to 18 months of age. However,
in PINK1 KO mice, overexpression of α-syn in the SNc resulted
in enhanced dopaminergic neuron degeneration as well as sig-
niﬁcantly higher levels of α-syn phosphorylation at serine 129 at
4 weeks post-injection (Oliveras-Salvá et al., 2014). Recently, a
PINK1 null mouse with an exon 4–5 deletion displayed a progres-
sive loss of DA in the striatum, but there was no degeneration in
the SNc (Akundi et al., 2011). The phenotypes of these mice are
very similar to those of Parkin KO and DJ-1 KO mice.
PARKIN
Parkin is an E3 ubiquitin ligase that functions in the ubiquitin–
proteasome system. Mutations in parkin are a cause of familial PD
and are also seen in some young-onset sporadic PD cases (Lücking
et al., 2000; Periquet et al., 2003). Several parkinKOmicehave been
generated, typically produced by deletion at exon 3, exon 7, or exon
2 in the PRKN gene (Goldberg et al., 2003; Itier et al., 2003; Pala-
cino et al., 2004; Von Coelln et al., 2004; Perez and Palmiter, 2005;
Zhu et al., 2007; Martella et al., 2009). However, they show no sub-
stantial DA-related behavioral abnormalities. Some of these KO
mice exhibit slightly impaired DA release (Itier et al., 2003; Kitada
et al., 2009a) and reduced norepinephrine levels in the olfactory
bulb and spinal cord with an abnormal nigrostriatal region but
without loss of SNc neurons (Goldberg et al., 2003; Von Coelln
et al., 2004).
Only the Parkin-Q311X-DAT-BAC mice exhibit multiple late
onsets and progressive hypokinetic motor deﬁcits, age-dependent
DA neuron degeneration in the SNc and a signiﬁcant reduction in
striatal DA and dopaminergic terminals in the striatum (Lu et al.,
2009). Recently, overexpression of T240R-parkin and of human
WT parkin induced progressive and dose-dependent DA cell death
in rats (Van Rompuy et al., 2014).
DJ-1
DJ-1 mutations are linked to an autosomal recessive, early onset
PD (Puschmann, 2013). KO models of DJ-1 mice with a targeted
deletion of exon 2 or insertion of a premature stop codon in exon
1 show decreased locomotor activity, a reduction in the release of
evoked DA in the striatum but no loss of SNc DA neurons and no
change of the DA levels (Goldberg et al., 2005; Kim et al., 2005).
However, one line of DJ-1 KO mice shows loss of DA neurons in
the VTA (Pham et al., 2010).
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Interestingly, a recently described DJ-1 KO mouse, backcrossed
on a C57/BL6 background, displayed a dramatic early onset uni-
lateral loss of DA neurons in the SNc, progressing to bilateral
degeneration of the nigrostriatal axis, with aging. In addition,
these mice exhibit age-dependent bilateral degeneration in the LC
and display, with aging, a mild motor behavioral deﬁcit at speciﬁc
time points (Rousseaux et al., 2012). Therefore, if conﬁrmed, this
new mouse model would provide a tool to study the preclinical
aspects of PD.
ATP13A2
Mutations in ATP13A2 (PARK9), encoding a lysosomal P-type
ATPase, are associated with both Kufor–Rakeb syndrome (KRS)
and neuronal ceroid lipofuscinosis. KRS has recently been classi-
ﬁed as a rare genetic form of PD (Heinzen et al., 2014; Yang and
Xu, 2014). Despite the accumulation of lipofuscin deposits in the
SNc and late-onset sensorimotor deﬁcits, there was no change in
the number of DA neurons in the SNc or in striatal DA levels in
aged Atp13a2 KO mice (Schultheis et al., 2013).
OTHER MODELS
Inactivation of multiple PD genes has been shown to be insufﬁ-
cient to cause signiﬁcant nigral degeneration within the lifespan
of mice (Hennis et al., 2014). Triple KO mice lacking Parkin, DJ-
1, or PINK1 have normal morphology and normal numbers of
dopaminergic and noradrenergic neurons in the SNc and LC.
Also, levels of striatal DA in these triple KO mice were normal
at 16 months, but increased at 24 months of age (Kitada et al.,
2009b).
Sonic hedgehog (SHH), nuclear receptor related protein-1
(Nurr1), pituitary homeobox3 (Pitx3), and engrailed 1 (EN1) are
transcription factors important to the development and main-
tenance of the nigro-striatal system (Jankovic et al., 2005; Jiang
et al., 2005; Li et al., 2009a; Gonzalez-Reyes et al., 2012; Zhang
et al., 2012). Both SHH and Nurr1 KO mice show a progres-
sive loss of DA neurons without LB formation (Jiang et al.,
2005; Kadkhodaei et al., 2009; Gonzalez-Reyes et al., 2012). Also,
Pitx3 gene mutations cause a complete loss of SNc and VTA
DA neurons and altered locomotor activity in mice (Hwang
et al., 2003; van den Munckhof et al., 2003). Recently, engrailed
1 heterozygous mice (En1+/–) showed a signiﬁcant and pro-
gressive retrograde degeneration of SNc neurons and dystrophic
and swollen striatal TH+ terminals (Nordström et al., 2014).
c-Rel (a subunit of the NFκB complex) KO mice also develop
a PD-like neuropathology on aging. At 18 months of age, c-rel
(–/–) mice exhibit a signiﬁcant loss of DA neurons in the SNc,
loss of dopaminergic terminals and a signiﬁcant reduction of
DA and HVA levels in the striatum. In addition, these mice
show age-dependent deﬁcits in locomotor activity and a marked
immunoreactivity for ﬁbrillary α-syn in the SNc (Baiguera et al.,
2012).
Conditional disruption of the gene for mitochondrial tran-
scription factor A in DA neurons (MitoPark) results in a parkin-
sonism phenotype in mice that includes an adult-onset, slowly
progressive impairment of motor function, DA neuron death,
degeneration of nigrostriatal pathways and intraneuronal inclu-
sions (Ekstrand et al., 2007; Good et al., 2011). Also, cell-speciﬁc
deletion of the essential autophagy gene Atg7 in midbrain DA
neurons causes DA neuron loss in the SNc at 9 months, accompa-
nied by late-onset locomotor deﬁcits. Atg7-deﬁcient DA neurons
in the midbrain also exhibit early dendritic and axonal dys-
trophy, reduced striatal DA content, and the formation of
somatic and dendritic ubiquitinated inclusions (Friedman et al.,
2012).
Recently, it has been suggested that a vesicular monoamine
tranporter (VMAT2) defect may be an early abnormality promot-
ing mechanisms leading to nigrostriatal DA neuron death in PD
(Piﬂ et al., 2014). VMAT2-deﬁcient mice display a progressive loss
of nigral DA and LC cells, loss of striatal DA and α-syn accu-
mulation (Taylor et al., 2011, 2014). Neuroprotection from MPTP
toxicity inVMAT2-overexpressors and enhancedMPTP toxicity in
VMAT2-KO mice suggest that interventions aimed at enhancing
vesicular capacity may be of therapeutic beneﬁt in PD (Takahashi
et al., 1997; Lohr et al., 2014).
CONCLUDING REMARKS
Despite the signiﬁcant contribution of all of these animal models
to our understanding of PD, none of these models reproduce the
human condition. If we consider toxic models, signiﬁcant nigros-
triatal degeneration is generally obtained with some motor deﬁcits
(particularly in MPTP-treated monkeys). Although no consistent
LB-like formation is detected, this issue in the study of PD patho-
genesis remains to be demonstrated. On the other hand, although
transgenic models offer insights into the causes of PD pathogen-
esis or LB-like formation, the absence of consistent neuronal loss
in the SNc remains a major limitation for these models. Another
troubling observation in genetic models is the often inconsistent
phenotypes among the lines with the same mutations. Whether or
not this is related to an artifact of insertion of the transgene or to
the actual genetic background, it would be advisable to test these
in more than one line.
In addition to the classicalmotor abnormalities observed in PD,
animal models are increasingly used to study non-motor symp-
toms (sleep disturbances, neuropsychiatric and cognitive deﬁcits;
Campos et al., 2013; Drui et al., 2014). Both toxin-based and
genetic models are suitable for studying these non-motor symp-
toms that are increasingly recognized as relevant in disease-state
(McDowell and Chesselet, 2012). Toxins-based models have been
mostly used to seek the mechanisms involved in levodopa induced
dyskinesias (LID) thus far (Morin et al., 2014). However, recently
viral vector-mediated silencing of TH was used to induce stri-
atal DA depletion without affecting the anatomical integrity of
the presynaptic terminals and study LID (Ulusoy et al., 2010).
And more recently, for the ﬁrst time, a genetic mouse model
overexpressing A53T α-syn in nigrostriatal and corticostriatal
projection neurons shows involuntary movements and increased
post-synaptic sensitivity to apomorphine (Brehm et al., 2014). It
seems unlikely that a single model can fully recapitulate the com-
plexity of the human disease. Future models should involve a
combination of neurotoxin and genetic animal models in order
to study the progressive neurodegeneration associated with PD.
Understanding the mechanisms responsible for this progressive
and intrinsic SNc neuronal loss is completely necessary at this
point.
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